TD Cowen cuts Daiichi Sankyo stock price target on valuation By Investing.com

TD Cowen cut its price target on Daiichi Sankyo (DSNKY) to JPY 3,590 from JPY 4,540 while retaining a Buy rating; the stock trades at $18.04 near its 52-week low. Cowen forecasts FY2030 revenue of JPY 2.7 trillion, core operating income of JPY 616 billion and EPS of JPY 275, and highlights a transformed ADC-driven business (PEG 0.64, P/E 17.81). Daiichi plans to present its FY2026-2030 5-year plan on May 19, 2025 and will invest ~ $1.9 billion to build targeted cancer drug production facilities across Japan, the U.S., Germany and China. Overall, the note mixes a downward PT with positive long-term guidance and meaningful capex, implying modest stock-specific reaction potential.

Analysis

Building meaningful internal ADC manufacturing capacity is a strategic pivot that shifts where profits and execution risk accrue: value moves from pure-play drug development to industrial-scale biomanufacturing and specialized process chemistry. That change benefits suppliers of high-spec fill/finish, conjugation chemistry, and controlled-environment construction while creating a longer, capital-intensive timeline before incremental drug revenue translates into sustained free cash flow.

The primary near-term risks are operational and regulatory rather than market demand: cross-border tech transfers, multi-jurisdiction GMP inspections, and scaling conjugation yields are classic three-to-twelve month failure points that can delay commercial supply and compress early margin assumptions. Over 12–36 months the inflection will be driven by site approvals, validated commercial runs, and first full-cost-of-goods prints — any slip can force re-contracting and margin repricing.

The market is split between two narratives: (a) the strategy is a value-creating verticalization that de-risks supply and enhances bargaining power with payors; (b) the move underestimates the time and cost to industrialize ADCs, leaving upside conditional on flawless execution. That ambiguity creates opportunities for asymmetric payoffs by pairing directional exposure to the company with targeted exposure to equipment/CDMO names that will either benefit from outsourcing demand or from increased capital spend.

Key Decisions for Investors

• Long DSNKY (OTC:DSNKY), 12–24 month horizon: allocate a tactical position sized to 1–2% of portfolio with a 30–50% upside target and a 20% hard stop. Rationale: capture re-rating if scale-up milestones are met; risk is execution delay and regulatory setback.
• Buy long-dated calls on DSNKY (12–24 month expiry) as a convex alternative: risk limited to premium (~100% loss of premium) with >2x upside if successful commercial runs and guidance revisions occur within the horizon. Size as a small, high-convexity sleeve (0.5–1% notional).
• Long specialty biomanufacturing/automation suppliers (examples: LZAGF, TMO, CTLT), 6–18 month horizon: expect near-term upside from equipment orders and process outsourcing volatility. Target 20–40% upside vs 10–15% drawdown risk; hedge broad biotech beta with an index-proportional short.
• Pair trade for event hedge: Long DSNKY / Short a large-cap oncology peer (e.g., BMY) in equal dollar terms for 12–24 months to isolate company-specific execution — this reduces broader pharma cyclicality and isolates ADC execution risk. Trim or unwind on site-approval newsflow or clinical readouts.